ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Nutrition Research Tests Hypotheses, Seeks Explanation Of Differences

August 14, 1981

Watson, Weinstein Decide FCRC Isn’t So Bad After all; DCCP to Develop RFAs, RFPs With Help Of Workshops

May 11, 1979

New NCI Director Varmus “Glad To Be Back,” Says Goal Is To Control Cancer Through Science

July 16, 2010

Severe Shortages Of Many Cancer Drugs Affecting Practices

November 19, 2010

AHRQ Funds Research To Reduce Medical Errors.

October 19, 2001

Funding opportunities listed.

July 23, 2004